Sickle Cell Disease
Conditions
Brief summary
This is an open label, single arm multicenter trial to evaluate the effect of voxelotor treatment on cerebral blood flow (CBF) and neurocognitive function in adolescent and young adult participants (12-30 years of age) with sickle cell disease (SCD).
Detailed description
Eligible participants will receive daily treatment with 1500 mg voxelotor for 24 weeks. During screening, at 12 and 24 weeks, participants will undergo an MRI for evaluation of cerebral blood flow and oxygen extraction fraction as well as NIH toolbox testing for evaluation of executive function, processing speed, and nonexecutive function.
Interventions
During the Treatment Period, participants will receive 1500 mg of voxelotor once daily (administered as tablets) for 24 weeks in addition to ongoing current standard of care (SOC) treatment
Sponsors
Pfizer
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 30 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female participants with confirmed diagnosis of SCD with HbSS or Hbβ0 thalassemia genotype. Documentation of SCD genotype is required and may be based on documented history of laboratory testing or confirmed by laboratory testing during Screening. 2. Aged 12 to 30 years. 3. Screening Hb level ≥ 5.5 and ≤ 10.5 g/dL. 4. Must meet site-specific compliance requirements for a diagnostic MRI scan. 5. Able to answer NIH Toolbox Module questions in English 6. If participant is receiving hydroxyurea (HU) they must have been on a stable dose for at least 90 days prior to signing the ICF/AF, with no dose modifications or initiation of HU planned or anticipated by the Investigator. 7. If participant is receiving erythropoiesis-stimulating agents (ESAs) they must have been on a stable dose for at least 12 weeks before enrollment with no dose modifications planned or anticipated by the Investigator. 8. Participants, who if female and of child-bearing potential, agree to use highly effective methods of contraception from study start to 30 days after the last dose of study drug and who if male, agree to use barrier methods of contraception and refrain from donating sperm from study start to 30 days after the last dose of study drug. 9. Females of child-bearing potential must have a negative pregnancy test before the administration of study drug. 10. Written informed consent (≥ 18 years) or parental/guardian consent and participant assent (≥ 12-17 years) per Institutional Review Board (IRB) policy and requirements, consistent with ICH guidelines. 11. Capable of complying with the requirements and restrictions in the protocol, and willing to participate in the study.
Exclusion criteria
1. History of overt stroke including hemorrhagic stroke, transient ischemic attacks, or spinal cord injury. 2. Grade 4 vasculopathy defined as moderate stenosis (50% to 69%) in more than 2 major cerebral arteries or severe stenosis (\> 70%) in any major cerebral artery. 3. Non-MRI compatible metal hardware and/or metal braces. 4. Congenital brain malformation, previously diagnosed severe developmental disability (eg autism and/or intelligence quotient \[IQ\] \<60, and/or severe attention deficit hyperactivity disorder \[ADHD\]), or impairment that would prevent the use of a computer tablet. 5. Participant is taking or has received voxelotor (Oxbryta®) within 90 days prior to the Screening Visit. 6. Participant is taking or has received crizanlizumab (Adakveo®) within 90 days prior to the Screening Visit. 7. Vaso-occlusive event requiring intravenous opioids within 28 days prior to Day 1. 8. Red blood cell (RBC) transfusion within 3 months before initiation of study drug or receives scheduled RBC transfusion therapy (also termed chronic, prophylactic, or preventive transfusion). 9. Surgery within 8 weeks before Day 1 or planned elective surgery during the study. 10. Anemia due to bone marrow failure (eg, myelodysplasia). 11. Absolute reticulocyte count (ARC) \< 100 × 10\^9/L. 12. Screening alanine aminotransferase or aspartate aminotransferase \> 4× upper limit of normal (ULN). 13. Severe renal dysfunction (estimated glomerular filtration rate \[eGFR\] \<45 mL/min/1.73 m\^2) or on chronic dialysis. 14. Clinically significant bacterial, fungal, parasitic, or viral infection which requires therapy 1. Acute bacterial infection requiring antibiotic use should delay Screening/enrollment until the course of antibiotic therapy has been completed. 2. Known active hepatitis A, B, or C or are known to be human immunodeficiency virus (HIV) positive. 15. Symptomatic coronavirus disease of 2019 (COVID-19) infection. 16. Females who are breast-feeding or pregnant. 17. History of hematopoietic stem cell transplant or gene therapy. 18. Participants taking concomitant medications such as sensitive CYP3A4 substrates with a narrow therapeutic range, or strong CYP3A4 inducers. 19. Participated in another clinical trial of an investigational product (or medical device) within 30 days or 5 half-lives of date of informed consent, whichever is longer, or is currently participating in another trial of an investigational product (or medical device). 20. Medical, psychological, or behavioral condition that, in the opinion of the Investigator, would confound or interfere with evaluation of safety and/or efficacy of the study drug, prevent compliance with the study protocol; preclude informed consent; or render the participant unable/unlikely to comply with the study procedures (particularly the MRI scan).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in CBF | Baseline to Week 24 | Change from Baseline in CBF through Week 24 measured by magnetic resonance imaging (MRI) using pseudo-continuous arterial spin labeling (pCASL). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in executive functioning. | Baseline to Week 24 | Change from Baseline through Week 24 in the executive cognitive abilities composite score (using Dimensional Change Card Sort Test, Flanker Inhibitory Control and Attention Test, and List Sorting Test) as assessed by the National Institutes of Health Toolbox Cognition Module. |
| Change in processing speed | Baseline to Week 24 | Change from Baseline through Week 24 in processing speed (using Pattern Comparison Test) as assessed by the NIH Toolbox Cognition Module |
| Change in nonexecutive functioning | Baseline to Week 24 | Change from Baseline through Week 24 in nonexecutive cognitive abilities composite score (using Picture Vocabulary Test, Oral Reading Recognition Test, and Picture Sequence Memory Test) as assessed by the NIH Toolbox Cognition Module. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in cerebral dynamics | Baseline to week 24 | Change from baseline through Week 24 in cerebral blood flow, oxygen extraction, and oxygen metabolism as measured by diffusion correlation spectroscopy (DCS)/frequency domain near infrared spectroscopy (FDNIRS) (if available) Correlation of cerebral hemodynamics measured by DCS/FDNIRS (if available) and cerebral hemodynamics measured by MRI. |
| Change in global OEF as measured using T2-Relaxation-Under-Spin-Tagging (TRUST) | Baseline to week 24 | Change from Baseline to Week 24 in global OEF as measured using TRUST (if available)). |
| Correlation between changes from Baseline in CBF (MRI and DCS/FDNIRS) | Baseline to Week 24 | Correlation between changes from Baseline in CBF (MRI and DCS/FDNIRS) and changes from Baseline in Hb levels |
| Correlation of changes from Baseline in OEF (MRI and DCS/FDNIRS) | Baseline to Week 24 | Correlation of changes from Baseline in OEF (MRI and DCS/FDNIRS) and changes from Baseline in Hb levels |
| Change in regional OEF as measured using ASE (If available) | Baseline to week 24 | Change from Baseline to Week 24 in regional OEF as measured using ASE (if available) |
| Change in HRQOL scores | Baseline to Week 24 | Change in HRQOL scores using Patient Global Impression of Severity (PGI-S) |
| Change in HRQOL scores using Clinician Global Impression of Severity. | Baseline to Week 24 | Change in HRQOL scores using Clinician Global Impression of Severity (CGI-S) |
| Incidence and severity of treatment-emergent AEs (TEAEs) | Baseline to Week 24 | Incidence and severity of treatment-emergent AEs (TEAEs) baseline through week 24. |
| Correlation of change from Baseline in Hb | Baseline to Week 24 | Correlation of change from Baseline in Hb and change from Baseline in executive abilities composite score |
| Change in regional CBF within the grey matter | Baseline to Week 24 | Change from Baseline through Week 24 in regional CBF within the grey matter. |
| Change in regional CBF within the white matter | Baseline to Week 24 | Change in HRQOL scores using: Change from Baseline through Week 24 in regional CBF within the white matter |
| Change in Hb and hemolysis over time | Baseline to week 24 | Change and percent change from Baseline through Week 24 in hemolysis measures, including unconjugated bilirubin, absolute reticulocyte, % reticulocytes, and lactate dehydrogenase (LDH). |
Countries
United States
Outcome results
None listed